RetinGero dry AMD trial: protocol and preliminary enrollment
Trial protocol and enrollment update · 2025
- Registered population or design
- Adults aged 60–80 with early or intermediate dry AMD in the study eye and a history of wet AMD in the fellow eye. 240 planned, 120 per group.
- Results availability
- RetinGero plans a 240-person placebo-controlled comparison. The protocol article reports 187 enrolled and baseline data for 170 as of January 3, 2025. Comparative efficacy results are pending in the checked publication.
Reported findings and study design
The patent gives no measured outcomes
Multicenter double-blind randomized comparison. The Mandryka military hospital ophthalmology center coordinates the trial with Pirogov University. Assessments include visual acuity, contrast sensitivity, OCT drusen measures and conversion to advanced AMD.
Dose, route and schedule
The protocol lists a 5 mg Retinalamin vial. It specifies one intramuscular injection per day for 10 days, repeated for eight courses spaced three months apart. The comparator is a matching schedule of placebo injections.
Protocol source ↗ · Original protocol, planned assessments and dated enrollment data.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Planned randomization | 240 participants, 120 per arm | |
| Documented enrollment and baseline data | 187 enrolled. Baseline data available for 170 (84 and 86 by masked group). | January 3, 2025 |
| Completed the full cycle | 4 participants | September 1, 2025 |
The published figures describe recruitment and data availability.
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- Screening, enrollment, available baseline data and completion represent different denominators. The protocol article gives no between-group efficacy result.
Source details
Published trial protocol and recruitment update
Original protocol, planned assessments and dated enrollment data.
Sources checked
Citation
Published
A. V. Kuroyedov, E. V. Balandina, O. V. Gaponko, and colleagues. RetinGero dry AMD trial: protocol and preliminary enrollment Russian Journal of Clinical Ophthalmology. 2025;25(4):250–256.
Study source ↗ · DOI 10.32364/2311-7729-2025-25-4-4 · Bibliography entry · Link to this summary